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Introduction
Percutaneous image-guided renal ablation provides 
minimally invasive and safe treatment to small (<4 cm) renal 
cell carcinoma (RCC) whilst offering preservation of the 
renal function and there is extensive evidence to support 
this, particularly in patients who may not be suitable 
surgical candidates or if they are unwilling to undergo 
surgery (1-4). In addition, it achieves similar oncologic 
outcomes as surgery (5,6).
This article aims to outline an overview of the current 
types of ablative technology, present the current evidence 
and discuss controversies on image-guided renal ablation. 
Current treatment options
Radiofrequency ablation (RFA)
The radiofrequency generator supplies radiofrequency 
power, using an alternating current, to the tissue through an 
electrode which causes ionic agitation, generating frictional 
heating ultimately resulting in thermal coagulation necrosis 
and cell death once the temperature exceeds 60 ℃ (7,8).
The oncological efficacy is backed up by extensive 
outcome data from multiple large institutions around the 
world (9-15). Size (<3 cm) and exophytic tumour location are 
strong predictors of success. Larger lesions have a reduced 
success rate with higher rates of subsequent recurrence, as 
high as 14% in the T1b group (11,16-18). Central tumours 
are also less effectively treated due to the heat sink effect 
from surrounding larger central vessels (16-18).
Cryoablation (CRYO)
In CRYO, an ice ball at the end of a cryoprobe is created 
using the Joule-Thomson effect, where a high-pressurised 
gas undergoes rapid expansion through a valve resulting in 
a rapid cooling effect while keeping it insulated so that no 
heat is exchanged with the environment. This rapid cooling 
results in ice formation at the end of the cryoprobe (19,20). 
Cycles of freezing and thawing destroys the cell membranes 
and organelles due to the mechanical stresses associated 
with phase change and ice formation (1). Intracellular ice 
crystal formation causes microvascular injury and ischaemia 
along with cell membrane injury, and hypotonic cell 
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disruption leading to cell death (21).
The advantages of CRYO over RFA are the ability to 
visualize the ice ball on imaging which confirms the ablation 
zone and the ability of CRYO to overcome heat sink effects 
particularly centrally within the kidney.
Cohort studies and a meta-analysis comparing RFA and 
CRYO found similar efficacy and comparable complication 
rates (14,22-24). A recent large single centre series found 
no statistical difference in local recurrence, metastases, and 
death from RCC among partial nephrectomy, RFA, and 
CRYO cohorts for cT1a patients (15). For tumours >3–4 
cm in size CRYO has been shown to have better oncologic 
outcomes when compared to RFA (11,25,26). 
The bleeding complication rate with CRYO is higher 
than RFA, with on study quoting a bleeding risk of 7.4% for 
CRYO compared to 1.2% for RFA (24). A newer generation 
of cryoprobe (Galil Medical, Arden Hills, Minnesota, USA) 
incorporated a heating element within the distal cryoprobe 
to allow for subsequent track ablation however despite this, 
a recent study found this did not decrease the incidence of 
bleeding complications (27).
Microwave ablation (MWA)
MWA utilises electromagnetic waves through one or 
multiple antennae, which agitates water molecules causing 
friction and heat dissipation, resulting in cell destruction by 
coagulative necrosis (28).
Although there are fewer studies on MWA compared to 
CRYO, technical success and safety have been proven and 
the short and intermediate results are comparable to RFA 
and CRYO, with quoted 3- and 5-year disease-free survival 
rate of 93% and 88% respectively, although these are from 
retrospective cohort studies (29-34). A meta-analysis found 
no difference in local or metastatic recurrence between the 
treatments for small renal masses, despite the larger median 
tumour size of 3.13 cm in the microwave group compared 
to 2.58 cm in the CRYO group (35).
The advantages of MWA include shorter ablation and 
procedure times compared with the other thermal ablation 
techniques (36), less effect from the heat-sink effect from 
the local blood supply compared to RFA and the ability of 
MWA to achieve larger ablation zones than RFA (28,37,38). 
MWA certainly has potential to treat larger (T1b) 
lesions (39) however the unpredictability of the ablation 
zone compared to CRYO with the current technology may 
limit its current widespread adoption until more evidence is 
available.
Irreversible electroporation (IRE)
IRE is a novel non-thermal ablation method that delivers 
short high voltage electrical energy between electrodes 
in order to permeabilise, i.e., cause nanopores in the cell 
membrane resulting in cell death by apoptosis (40). 
Non-cellular tissue, including collagen structures such 
as vessels contain no lipid bilayer structure and therefore 
are resistant to damage by the permeability. This ability to 
preserve vital surrounding structures within the ablation 
zone is what makes IRE unique, which is particularly 
effective for cancers adjacent to important structures such 
as major blood vessels or the ureter (38,40,41). IRE also has 
the characteristic feature of a sharp demarcation between 
the ablated zone and the normal surrounding tissue, thereby 
providing more precise ablation. 
The literature in IRE for renal tumours remains limited. 
Although IRE is supposed to be a non-thermal ablation 
modality, a secondary rise in temperature has been shown (42) 
although it is unknown if there is clinically significant 
thermal damage accompanying the primary non-thermal 
damage. Knowledge on how to interpret the ablation zone 
on immediate and follow-up imaging and also what the best 
modality is required.
Additional considerations in using IRE include the 
need for general anaesthesia, deep muscle relaxation and 
electrocardiogram synchronized pulsing of electricity. The 
application of pulsatile electrical energy, with a high current 
of approximately 20–50 A and a voltage of up to 3,000 V, 
poses an issue for anaesthetists due to the risk of cardiac 
arrhythmias, severe muscle contractions and epileptic 
seizures (43). Therefore, the contraindications for IRE are 
atrial fibrillation, epilepsy and cardiac pacemaker.
Although IRE seems feasible and safe, longer follow-up 
date is required to demonstrate oncological results. There 
remains an operator learning curve (38), therefore national 
and/or international multi-centre registries would help 
collate more data on IRE safety and efficacy in the future 
and provide more evidence.
Stereotactic ablative radiotherapy (SABR)
Conventional radiotherapy only had a limited role in the 
treatment of primary RCC, as the doses delivered were too 
low. With new high-dose SABR technology, new treatment 
possibilities for RCC with curative intent open up. SABR 
is currently a treatment option for patients who are at high 
risk for a general anaesthesia. Data suggests high-dose 
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radiation has an immune stimulatory effect as the more 
localised SABR radiation drives the release of antigens by 
tumours, inducing a tumour-specific T cell response (44). 
This effect has also been described for other thermal 
ablative techniques.
Available evidence suggests SABR is safe with low 
toxicity with the main documented side effects being 
fatigue, nausea, radiation dermatitis and enteritis.
SABR also has the ability to treat larger T2 lesions with 
treated tumour sizes up to 7.5 cm in the literature (45,46). 
Choice of imaging guidance
Ultrasound, computed tomography (CT), or magnetic 
resonance (MR) imaging (MRI) can be used to target a 
lesion during ablation. The modality chosen is largely based 
on operator preference or expertise, local availability of 
dedicated equipment such as CT fluoroscopy or open MR 
systems and capacity to take up scanning time on these 
machines. Real-time fusion imaging of ultrasound imaging 
with CT or MRI can also improve the ability to guide and 
monitor tumour ablation procedures.
The renal tumour ideally must be easily and clearly 
visualized on the imaging modality chosen. Ultrasound 
allows for real-time placement of ablation probes and does 
not require ionizing radiation. The major downside is that 
ultrasound remains highly operator dependent and may be 
difficult in certain situations including for large body habitus 
patients or the presence of adjacent bowel gas obscuring 
the visualisation of the tumour. Image degradation occurs 
during ultrasound due to acoustic shadowing from the ice 
ball for CRYO, and microbubbles in RFA which obscure 
the target (47).
CT has advantages over ultrasound including being 
less operator dependent, it has no artefact from bowel gas 
and gives a clear image of surrounding vital structures. 
Percutaneous ablation is done using either a conventional 
CT scanner or a CT scanner with real-time fluoroscopy 
which can have dose reduction implications (48). 
MRI is a less commonly used for percutaneous ablation 
as due to high cost or lack of free scanning time. It does 
offer excellent soft tissue resolution and avoids the use of 
ionizing radiation. Additional features such as fluoroscopic 
sequences may be used for real-time guidance or MR 
thermography to assess cytotoxic tissue temperatures non-
invasively (47). MRI-guided percutaneous ablation is 
performed using either a dedicated interventional magnet, a 
conventional solenoid magnet, or an open magnet. Further 
considerations include the need for MRI-compatible 
ablation equipment (47).
Current international guidelines
The current American Urological Association (AUA) 
guidance suggests that T1a renal masses (<3 cm) should 
be considered for renal thermal ablation of which RFA 
and CRYO are recommended although “priority for partial 
nephrectomy is recommended for clinical T1a lesions” (2). The 
guidelines state that thermal ablation is preferable to a 
surgical approach, laparoscopic or open, to minimize 
complications.
The European Society of Medical Oncology (ESMO) 
guidelines acknowledge the thermal ablative therapies 
are options in patients with small tumours (≤3 cm), 
particularly patients who are frail, are a high surgical risk, 
if they have a solitary kidney, compromised renal function, 
hereditary RCC or multiple bilateral tumours. Despite 
this, the ESMO guidance highlights the statement that the 
“quality of the available evidence prevents definitive conclusions 
regarding morbidity and oncological outcomes for RFA and 
cryoablation” (49).
The American Society for Clinical Oncology (ASCO) 
guidelines also recognise the increasing role of ablation 
stating “percutaneous thermal ablation should be considered 
for patients who possess tumours such that complete ablation 
will be achieved” although partial nephrectomy is still 
recommended in patients where the tumour is appropriate 
for it (50). ASCO also highlights the level of evidence 
backing up their recommendations as “intermediate-quality” 
and given as “moderate” strength unlike the AUA who gave 
the quality of evidence comparing partial nephrectomy 
and ablation as “low” (2,50). One study cited by ASCO is 
a large cohort study comparing partial nephrectomy, RFA 
and CRYO where the 3-year local recurrence-free survival 
for each treatment was not statistically difference (98% 
for all groups) (14). As with other studies, there remained 
selection bias in the nephrectomy group of younger and 
healthier patients explaining the slightly higher 3-year 
overall survival (OS) of 95% compared to 82% for RFA and 
88% for CRYO (14).
Controversies
Local recurrence rates
The AUA guidelines indicate that a major disadvantage 
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of percutaneous image-guided renal ablation is the higher 
quoted local recurrence rate compared to partial and radical 
nephrectomy (51).  
This quoted difference may be exaggerated in certain 
patient cohorts and not entirely evidence based, but rather 
due to a lack of long-term disease-free survival data on 
ablative management of small RCCs (5).
The RFA evidence base is mainly from retrospective 
cohort studies with small study sample sizes and limited 
follow-up. Three retrospective studies compared RFA to 
surgery in patients with T1a tumours and found lower 
complication rates and comparable oncologic outcomes to 
partial nephrectomy despite being an older patient cohort 
with more comorbidities (17,52,53).
The median estimated glomerular filtration rate (eGFR) 
decrease following RFA was also significantly lower than 
the nephrectomy group (7.9% vs. 29%) consistent with the 
existing evidence showing ablations with better preservation 
of renal function (5,17).
A systematic review of RFA and partial nephrectomy 
suggested a long-term cancer specific survival for RFA, 
equal to partial nephrectomy together with a low metastasis 
rate but slightly higher local recurrence rate compared 
with partial nephrectomy and CRYO (54). A recent meta-
analysis found CRYO for T1 renal tumours was associated 
with poorer oncological outcomes (cancer-specific death, 
metastases and local-recurrence rates), but this was also 
accompanied by a lower rate of overall and post-operative 
complications and superior renal functional preservation (55).
Post-ablation imaging follow-up
CT using a triple-phase protocol (unenhanced, arterial 
and portal-venous phase studies) or multi-parametric MRI 
is used to assess the treatment efficacy and locoregional 
recurrence (56,57).  
Each thermal ablative technique results in different 
rates of temporal resolution of post-ablation follow-up 
imaging. For RFA the reduction of the zone of ablation at 2 
years is 50% compared to CRYO which is 75%. Complete 
resolution is seen in approximately 33% of patients 
following CRYO (57-59). The zone of ablation may initially 
show a degree of enhancement in the first weeks after 
treatment, which can pose a diagnostic dilemma and it can 
vary depending on the time interval post-thermal ablation 
(60,61). 
Concomitantly, lack of enhancement does not fully rule 
out residual or recurrence disease and a previous study 
found 8% of patients with no enhancement within the 
zone still had viable disease following biopsy of the non-
involuting zone of ablation (62). The literature suggests 
true residual or recurrent disease can be distinguished from 
the normal expected marginal enhancement post-ablation 
by using brisk contrast medium administration (38). 
A similar controversy with follow-up imaging also 
afflicts post-IRE follow-up with little available published 
guidance. One study found an initial larger hypodense 
non-enhancing area consistent with the ablation zone 
at 6 weeks, similar to other thermal ablative techniques, 
which then involuted by the 6-month CT scan (63). On 
MRI following IRE, there is a progressive decrease in the 
treated tumour signal intensity, with a mean follow-up of 
approximately 6 months (64). More work in this area is 
required before deciding on the best imaging modality to 
use for follow-up and how to interpret this.
Biopsies
The rationale behind obtaining a pathological diagnosis 
prior to ablation is that the differential diagnosis for solid, 
enhancing renal masses includes RCC as well as benign 
tumors, non-RCC malignancies and metastatic lesions (2). 
Ablation leads to tissue necrosis, which will prevent 
subsequent histological diagnosis.
The AUA, ESMO and ASCO guidelines all recommend 
a renal biopsy prior to ablation to confirm malignancy, 
subtype the pathology and guide surveillance after ablation 
(2,49,50).
Undertaking a biopsy of the zone of ablation remains a 
debatable issue as it is unclear which site should be biopsied 
and how many sampling cores should be performed. This 
may be considered if imaging findings are indeterminate or 
there is a persistent non-involuting zone of ablation despite 
lack of imaging enhancement which can be due to residual 
disease (62). These cases should be a consensus decision 
by the multidisciplinary tumour board whenever there 
is suspicion of viable cancer in the zone of ablation post-
treatment.
Ablation vs. robotic surgery
Robot-assisted laparoscopic partial nephrectomy (RALPN) 
is associated with more favourable results than conventional 
laparoscopic partial nephrectomy in terms of conversion 
rate to open or radical surgery, warm ischaemia time, renal 
functional outcomes, and shorter length of hospital stay (65). 
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Five-year OS, cancer-free survival (CFS), and cancer-
specific survival (CSS) were 91.1%, 97.8%, and 97.8%, 
respectively confirming excellent long-term oncologic 
outcomes after RALPN in well selected patients (66).
Comparat ive  data  wi th  CRYO is  mainly  f rom 
retrospective cohort studies. One study found comparable 
complication rates, better renal function preservation for 
CRYO but higher recurrence rates (67). A second study 
found the local recurrence rate after CRYO was significantly 
higher than after robotic tumourectomy for T1 renal 
tumours (68). Taking into account the lower complications 
profile and shorter length of stay associated with ablation, it 
is likely that RALPN is also less cost-effective (69).
Treating larger tumours
Retrospective data suggests that T1b tumours can be 
effectively treated with CRYO, however the quoted 
complication rate was higher at 8–15% (25,26).
Both MWA and SABR have the potential to treat 
larger (T1b) lesions (39) however MWA zones may still be 
unpredictable and SABR requires longer follow-up data to 
demonstrate clear oncological outcomes.
Patient selection: active surveillance vs. intervention 
For patients with a reduced life expectancy, either due to 
advanced age or severe comorbidities, undertaking even 
a minimally invasive treatment such as ablation or partial 
nephrectomy could result in unnecessary psychological 
and physical stress. In addition, there is data suggesting 
that some small renal masses may not significantly impact 
a patient's mortality (70). This highlights the importance 
of follow-up imaging and/or biopsy to confirm a malignant 
lesion and published data suggest that the linear growth 
rate of small renal masses is the most accurate predictor of 
metastasis (71). 
Important considerations for shared decision-making 
about active surveillance are explicitly defined by the 
international guidelines (2,49,50) although comparative 
data on active surveillance is still lacking (5). Anecdotally, 
patients may request for treatment of their slowly growing 
cancer after a period of active surveillance highlighting 
the importance of the discussion and explaining to the 
patient all the available options. Choosing the most 
appropriate management strategy requires a conversation 
between physician and patients to weigh up multiple 
factors including the evidence based oncological outcome 
profile for each strategy including local recurrence rate, 
the renal function outcomes (favouring ablation over even 
partial nephrectomy), perioperative outcomes, and risk 
of complications (5). Outcomes are likely to reflect case 
selection.
Conclusions
Current evidence supports the use of image-guided renal 
ablation for small, renal tumours with well-established 
thermal ablative treatments such as RFA and CRYO 
however the increasing literature showing the safety and 
efficacy of MWA, IRE and SABR will open up further 
possibilities of treating larger tumours with MWA and 
SABR or more central tumours especially with IRE. 
Future research should focus on the mechanisms 
governing systemic immune-modulating effects of ablative 
therapies with the aim to increase the indications for 
ablation, both with a curative intent and for palliation. The 
potential combinations with systemic treatment such as 
immunotherapy, for treatment intensification or to treat 
larger lesions or metastatic disease, can help to improve 
overall patient outcomes.
Acknowledgments
None.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
References
1. Venkatesan AM, Wood BJ, Gervais DA. Percutaneous 
Ablation in Kidney. Radiology 2011;261:375-91. 
2. Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass 
and Localized Renal Cancer: AUA Guideline. J Urol 
2017;198:520-9. 
3. Wagstaff P, Ingels A, Zondervan P, et al. Thermal ablation 
in renal cell carcinoma management: A comprehensive 
review. Curr Opin Urol 2014;24:474-82. 
Zhong and Wah. Renal ablation: current management strategies and controversies
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2019;8(6):63 | http://dx.doi.org/10.21037/cco.2019.12.08
Page 6 of 8
4. Sun M, Abdollah F, Bianchi M, et al. Treatment 
management of small renal masses in the 21st century: A 
paradigm shift. Ann Surg Oncol 2012;19:2380-7. 
5. Pierorazio PM, Johnson MH, Patel HD, et al. 
Management of Renal Masses and Localized Renal 
Cancer: Systematic Review and Meta-Analysis. J Urol 
2016;196:989-99. 
6. Rivero JR, De La Cerda J 3rd, Wang H, et al. Partial 
Nephrectomy versus Thermal Ablation for Clinical Stage 
T1 Renal Masses: Systematic Review and Meta-Analysis 
of More than 3,900 Patients. J Vasc Interv Radiol 
2018;29:18-29. 
7. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation 
therapy for focal malignancy: a unified approach to 
underlying principles, techniques, and diagnostic imaging 
guidance. AJR Am J Roentgenol 2000;174:323-31. 
8. Nahum Goldberg S, Dupuy DE. Image-guided 
radiofrequency tumor ablation: challenges and 
opportunities--part I. J Vasc Interv Radiol 2001;12:1021-32.
9. Wah TM, Irving HC, Gregory W, et al. Radiofrequency 
ablation (RFA) of renal cell carcinoma (RCC): experience 
in 200 tumours. BJU Int 2014;113:416-28.
10. Zagoria RJ, Pettus JA, Rogers M, et al. Long-term 
outcomes after percutaneous radiofrequency ablation for 
renal cell carcinoma. Urology 2011;77:1393-7. 
11. Psutka SP, Feldman AS, McDougal WS, et al. Long-term 
oncologic outcomes after radiofrequency ablation for T1 
renal cell carcinoma. Eur Urol 2013;63:486-92. 
12. Ma Y, Bedir S, Cadeddu JA, et al. Long-term outcomes in 
healthy adults after radiofrequency ablation of T1a renal 
tumours. BJU Int 2014;113:51-5. 
13. Tracy CR, Raman JD, Donnally C, et al. Durable 
oncologic outcomes after radiofrequency ablation: 
Experience from treating 243 small renal masses over 7.5 
years. Cancer 2010;116:3135-42. 
14. Thompson RH, Atwell T, Schmit G, et al. Comparison of 
Partial Nephrectomy and Percutaneous Ablation for cT1 
Renal Masses. Eur Urol 2015;67:252-9. 
15. Andrews JR, Atwell T, Schmit G, et al. Oncologic 
Outcomes Following Partial Nephrectomy and 
Percutaneous Ablation for cT1 Renal Masses. Eur Urol 
2019;76:244-51. 
16. Gervais DA, McGovern FJ, Arellano RS, et al. 
Radiofrequency ablation of renal cell carcinoma: part 1, 
Indications, results, and role in patient management over 
a 6-year period and ablation of 100 tumors. AJR Am J 
Roentgenol 2005;185:64-71. 
17. Takaki H, Yamakado K, Soga N, et al. Midterm results of 
radiofrequency ablation versus nephrectomy for T1a renal 
cell carcinoma. Jpn J Radiol 2010;28:460. 
18. Varkarakis IM, Allaf ME, Inagaki T, et al. Percutaneous 
radio frequency ablation of renal masses: Results at a 2-year 
mean followup. J Urol 2005;174:456-60. 
19. Castellan GW. Energy and the first Law of 
Thermodynamics; Thermochemistry. Physical Chemistry. 
2nd edition. Boston: Addison-Wesley, 1971. 
20. Adamson AW. Chemical Thermodynamics. The first Law 
of Thermodynamics. A textbook of Physical Chemistry. 
1st edition. New York, San Francisco, London: Academic 
Press, 1973. 
21. Weber SM, LJ FT. Cryoablation: history, mechanism of 
action, and guidance modality. (Tumour ablation). New 
York: Springer, 2005. 
22. Atwell TD, Schmit GD, Boorjian SA, et al. Percutaneous 
ablation of renal masses measuring 3.0 cm and smaller: 
comparative local control and complications after 
radiofrequency ablation and cryoablation. AJR Am J 
Roentgenol 2013;200:461-6. 
23. El Dib R, Touma NJ, Kapoor A. Cryoablation vs 
radiofrequency ablation for the treatment of renal cell 
carcinoma: A meta-analysis of case series studies. BJU Int 
2012;110:510-6. 
24. Atwell TD, Carter RE, Schmit GD, et al. Complications 
following 573 percutaneous renal radiofrequency 
and cryoablation procedures. J Vasc Interv Radiol 
2012;23:48-54. 
25. Atwell TD, Vlaminck JJ, Boorjian SA, et al. Percutaneous 
cryoablation of stage T1b renal cell carcinoma: Technique 
considerations, safety, and local tumor control. J Vasc 
Interv Radiol 2015;26:792-9. 
26. Schmit GD, Atwell TD, Callstrom MR, et al. 
Percutaneous Cryoablation of Renal Masses ≥3 cm: 
Efficacy and Safety in Treatment of 108 Patients. J 
Endourol 2010;24:1255-62. 
27. Schmit CH, Callstrom MR, Boorjian SA, et al. A 
Comparison of Bleeding Complications in Patients 
Undergoing Percutaneous Renal Cryoablation Using 
Cryoprobes with and without Heat-Based Track Ablation. 
J Vasc Interv Radiol 2018;29:874-9. 
28. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave 
ablation: principles and applications. Radiographics 
2005;25 Suppl 1:S69-83.  
29. Yu J, Liang P, Yu XL, et al. US-guided percutaneous 
microwave ablation of renal cell carcinoma: intermediate-
term results. Radiology 2012;263:900-8. 
30. Yu J, Zhang G, Liang P, et al. Midterm results of 
Chinese Clinical Oncology, Vol 8, No 6 December 2019
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2019;8(6):63 | http://dx.doi.org/10.21037/cco.2019.12.08
Page 7 of 8
percutaneous microwave ablation under ultrasound 
guidance versus retroperitoneal laparoscopic radial 
nephrectomy for small renal cell carcinoma. Abdom 
Imaging 2015;40:3248-56. 
31. Li X, Liang P, Yu J, et al. Role of contrast-enhanced 
ultrasound in evaluating the efficiency of ultrasound 
guided percutaneous microwave ablation in patients with 
renal cell carcinoma. Radiol Oncol 2013;47:398-404. 
32. Ierardi AM, Puliti A, Angileri SA, et al. Microwave 
ablation of malignant renal tumours: intermediate-term 
results and usefulness of RENAL and mRENAL scores 
for predicting outcomes and complications. Med Oncol 
2017;34:97. 
33. Chan P, Vélasco S, Vesselle G, et al. Percutaneous 
microwave ablation of renal cancers under CT guidance: 
safety and efficacy with a 2-year follow-up. Clin Radiol 
2017;72:786-92. 
34. Klapperich ME, Abel EJ, Ziemlewicz TJ, et al. Effect 
of Tumor Complexity and Technique on Efficacy and 
Complications after Percutaneous Microwave Ablation 
of Stage T1a Renal Cell Carcinoma: A Single-Center, 
Retrospective Study. Radiology 2017;284:272-80. 
35. Martin J, Athreya S. Meta-analysis of cryoablation versus 
microwave ablation for small renal masses: is there a 
difference in outcome? Diagn Interv Radiol 2013;19:501-7.
36. Zhou W, Arellano RS. Thermal Ablation of T1c Renal 
Cell Carcinoma: A Comparative Assessment of Technical 
Performance, Procedural Outcome, and Safety of 
Microwave Ablation, Radiofrequency Ablation, and 
Cryoablation. J Vasc Interv Radiol 2018;29:943-51. 
37. Brace CL. Microwave tissue ablation: biophysics, 
technology, and applications. Crit Rev Biomed Eng 
2010;38:65-78.
38. Wah TM. Image-guided ablation of renal cell carcinoma. 
Clin Radiol 2017;72:636-44. 
39. Wells SA, Wheeler KM, Mithqal A, et al. Percutaneous 
microwave ablation of T1a and T1b renal cell carcinoma: 
short-term efficacy and complications with emphasis on 
tumor complexity and single session treatment. Abdom 
Radiol (NY) 2016;41:1203-11. 
40. Davalos RV, Mir LM, Rubinsky B. Tissue ablation 
with irreversible electroporation. Ann Biomed Eng 
2005;33:223-31. 
41. Al-Sakere B, André F, Bernat C, et al. Tumor ablation with 
irreversible electroporation. PLoS One 2007;2:e1135. 
42. Wagstaff PG, de Bruin DM, van den Bos W, et al. 
Irreversible electroporation of the porcine kidney: 
Temperature development and distribution. Urol Oncol 
2015;33:168.e1-7. 
43. Nielsen K, Scheffer HJ, Vieveen JM, et al. Anaesthetic 
management during open and percutaneous irreversible 
electroporation. Br J Anaesth 2014;113:985-92. 
44. Siva S, Kothari G, Muacevic A, et al. Radiotherapy 
for renal cell carcinoma: Renaissance of an overlooked 
approach. Nat Rev Urol 2017;14:549-63. 
45. Siva S, Pham D, Kron T, et al. Stereotactic ablative body 
radiotherapy for inoperable primary kidney cancer: a 
prospective clinical trial. BJU Int 2017;120:623-30. 
46. Siva S, Louie AV, Warner A, et al. Pooled analysis of 
stereotactic ablative radiotherapy for primary renal cell 
carcinoma: A report from the International Radiosurgery 
Oncology Consortium for Kidney (IROCK). Cancer 
2018;124:934-42.  
47. Maybody M. An overview of image-guided percutaneous 
ablation of renal tumors. Semin Intervent Radiol 
2010;27:261-7. 
48. Levesque VM, Shyn PB, Tuncali K, et al. Radiation dose 
during CT-guided percutaneous cryoablation of renal 
tumors: Effect of a dose reduction protocol. Eur J Radiol 
2015;84:2218-21. 
49. Escudier B, Porta C, Schmidinger M, et al. Renal 
cell carcinoma: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up†. Ann Oncol 
2019;30:706-20. 
50. Finelli A, Ismaila N, Bro B, et al. Management of small 
renal masses: American society of clinical oncology clinical 
practice guideline. J Clin Oncol 2017;35:668-80. 
51. Campbell SC, Novick AC, Belldegrun A, et al. Guideline 
for Management of the Clinical T1 Renal Mass. J Urol 
2009;182:1271-9. 
52. Olweny EO, Park SK, Tan YK, et al. Radiofrequency 
ablation versus partial nephrectomy in patients with 
solitary clinical t1a renal cell carcinoma: Comparable 
oncologic outcomes at a minimum of 5 years of follow-up. 
Eur Urol 2012;61:1156. 
53. Arnoux V, Descotes JL, Sengel C, et al. Perioperative 
outcomes and mid-term results of radiofrequency ablation 
and partial nephrectomy in indications of renal tumor 
treatment and imperative nephron-sparing procedure. 
Prog Urol 2013;23:99-104. 
54. MacLennan S, Imamura M, Lapitan MC, et al. 
Systematic review of oncological outcomes following 
surgical management of localised renal cancer. Eur Urol 
2012;61:972-93. 
55. Deng W, Chen L, Wang Y, et al. Cryoablation versus 
Partial Nephrectomy for Clinical Stage T1 Renal 
Zhong and Wah. Renal ablation: current management strategies and controversies
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2019;8(6):63 | http://dx.doi.org/10.21037/cco.2019.12.08
Page 8 of 8
Masses: A systematic review and meta-analysis. J Cancer 
2019;10:1226-36. 
56. Wile GE, Leyendecker JR, Krehbiel KA, et al. CT and 
MR Imaging after Imaging-guided Thermal Ablation of 
Renal Neoplasms. RadioGraphics 2007;27:325-39. 
57. Davenport MS, Caoili EM, Cohan RH, et al. MRI and 
CT characteristics of successfully ablated renal masses: 
Imaging surveillance after radiofrequency ablation. AJR 
Am J Roentgenol 2009;192:1571-8.
58. Gill IS, Remer EM, Hasan WA, et al. Renal cryoablation: 
Outcome at 3 years. J Urol 2005;173:1903-7. 
59. Allen BC, Remer EM. Percutaneous cryoablation of renal 
tumors: patient selection, technique, and postprocedural 
imaging. Radiographics 2010;30:887-900. 
60. Javadi S, Ahrar JU, Ninan E, et al. Characterization of 
contrast enhancement in the ablation zone immediately 
after radiofrequency ablation of renal tumors. J Vasc Interv 
Radiol 2010;21:690-5. 
61. Merkle EM, Nour SG, Lewin JS. MR Imaging Follow-up 
after Percutaneous Radiofrequency Ablation of Renal Cell 
Carcinoma: Findings in 18 Patients during First 6 Months. 
Radiology 2005;235:1065-71. 
62. Karam JA, Ahrar K, Vikram R, et al. Radiofrequency 
ablation of renal tumours with clinical, radiographical and 
pathological results. BJU Int 2013;111:997-1005. 
63. Trimmer CK, Khosla A, Morgan M, et al. Minimally 
Invasive Percutaneous Treatment of Small Renal Tumors 
with Irreversible Electroporation: A Single-Center 
Experience. J Vasc Interv Radiol 2015;26:1465-71. 
64. Diehl SJ, Rathmann N, Kostrzewa M, et al. Irreversible 
Electroporation for Surgical Renal Masses in Solitary 
Kidneys: Short-Term Interventional and Functional 
Outcome. J Vasc Interv Radiol 2016;27:1407-13. 
65. Choi JE, You JH, Kim DK, et al. Comparison of 
perioperative outcomes between robotic and laparoscopic 
partial nephrectomy: A systematic review and meta-
analysis. Eur Urol 2015;67:891-901. 
66. Andrade HS, Zargar H, Caputo PA, et al. Five-year 
Oncologic Outcomes after Transperitoneal Robotic 
Partial Nephrectomy for Renal Cell Carcinoma. Eur Urol 
2016;69:1149-54. 
67. Tanagho YS, Bhayani SB, Kim EH, et al. Renal 
cryoablation versus robot-assisted partial nephrectomy: 
Washington University long-term experience. J Endourol 
2013;27:1477-86. 
68. Fraisse G, Colleter L, Peyronnet B, et al. Oncological 
outcome of robotic tumorectomy versus cryoablation for 
renal masses: Comparison after matching on radiological 
stage and renal score. Eur Urol Suppl 2018;17:e2064. 
69. Larcher A, Sun M, Dell’Oglio P, et al. Mortality, morbidity 
and healthcare expenditures after local tumour ablation 
or partial nephrectomy for T1A kidney cancer. Eur J Surg 
Oncol 2017;43:815-22. 
70. Kunkle DA, Egleston BL, Uzzo RG. Excise, Ablate or 
Observe: The Small Renal Mass Dilemma-A Meta-
Analysis and Review. J Urol 2008;179:1227-33. 
71. Hwang EC, Yu HS, Kwon DD. Small renal masses: 
Surgery or surveillance. Korean J Urol 2013;54:283-8. 
Cite this article as: Zhong J, Wah TM. Renal ablation: current 
management strategies and controversies. Chin Clin Oncol 
2019;8(6):63. doi: 10.21037/cco.2019.12.08
